Requests for data from other clinical trials should be requested via the enquiry form and will be assessed on a case-by-case basis.

• there is a reasonable likelihood that a participant could be re-identified
• the data is subject to legal, contractual or consent provisions that prevent further sharing of data
• there are practical constraints to providing the data (for example, issues related to the format of the databases)
• the study information is not in English
• a significant proportion of participants must be removed due to national regulations
• there is an actual or potential conflict of interest related to the data or the requester such as requests for competitive, commercial, or legal purposes

We do not share raw imaging files and/or exploratory biomarker data.

• Anonymized Individual Participant Data (IPD)
• Full redacted protocol including amendments
• Redacted Statistical Analysis Plan
• Data Dictionary/define file
• Redacted annotated electronic Case Report Forms (eCRFs)
• Anonymization report

BE AWARE! During the data anonymization process some variables in the datasets might be removed or transformed, which can impact analyses of the data. It is therefore of outmost importance that requesters check the supporting documents uploaded on Vivli for each trial to understand which changes have been made before data is requested. Although the anonymization strategy is trial-specific a few general rules are applied:

• Participant ID: replaced (masked) by a new ID but is kept consistent across files within a trial (including extension trials).
• Further unique IDs: Removed (suppressed)
• Date of birth: Changed to age. Ages are often aggregated into 5–15-year groups, but for studies in children we keep unaggregated if at all possible.
• Height/Weight: One or both is often removed (suppressed), but we keep weight if possible.
• Dates: PHUSE shifted. This means dates are shifted by a number of days. The same shift is used across dates for a participant, however different shifts are used for different participants.
• Free text fields (comments, initials): Removed (suppressed).

Lundbeck is proactively anonymizing IPD from listed phase III and IV trials, whereas IPD from phase I and II trials are only anonymized upon request. The data delivery timeline will therefore be longer if trials are requested that have not yet been anonymized.

Documents will be redacted to protect personal data of trial participants, study personnel, Lundbeck employees, and to protect Lundbeck’s commercially confidential information.

1. Scientific objective: The research proposal must contain a research plan that explains the scientific rationale for the analysis and its relevance to medical research and/or patient outcomes.
2. Study design: The analytical methods and statistical analysis plan must be valid and support the proposed research in a coherent way with the ability to meet the scientific objectives.
3. Publication plan: The research proposal must contain a proposal for a publication plan demonstrating that the researcher/research group intends to publish the results of the study in a peer-reviewed scientific journal or otherwise make the results publicly available.
4. Qualifications of the researchers: The researcher/research group must be qualified to perform the described analysis/study. The names and qualifications of all members of the research group must be included in the proposal. At least one statistician (degree in statistics or a related discipline) shall be designated as part of the research group.
5. Conflicts of interest: Any real or potential conflicts of interest must be disclosed, as this could impact the conduct or interpretation of the research.